IP Library Granted Patent US 12,258,372
Granted Patent B2
US 12,258,372 · App. 17/682,358 · Granted Mar 25, 2025

Recombinant vaccine against Marek's disease and Newcastle disease

Inventors: Qingzhong Yu (Athens, GA); Stephen J. Spatz (Bogart, GA); John R. Dunn (East Lansing, GA)
Assignee: The United States of America, as represented by The Secretary of Agriculture
C07K14/125C07K14/055C12N7/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,372
App. No.
17/682,358
Granted
Mar 25, 2025
Kind
B2
Abstract

Provided herein are immunogenic compositions containing recombinant viruses capable of inducing protection in poultry against both Marek's disease virus (MDV) and Newcastle disease virus (NDV). Such viruses incorporate nucleic acids for expressing at least one MDV antigen, such as glycoprotein B, and antigenic portions thereof, in a recombinant NDV genome.

Claims (10)

1. A recombinant Newcastle disease virus (NDV), comprising a synthetic polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:2, and wherein the genome of the recombinant NDV is at least 95% identical to SEQ ID NO: 3.

2. The recombinant NDV of claim 1 , comprising a synthetic polypeptide having an amino acid sequence at least 98% identical to SEQ ID NO:2.

3. The recombinant NDV of claim 1 , further comprising a pharmaceutically acceptable carrier.

4. The recombinant NDV of claim 1 , wherein the NDV strain is LaSota.

5. A vector comprising a nucleic acid encoding the recombinant NDV of claim 1 .

6. A method of eliciting an immune response against Marek's disease virus (MDV) and Newcastle disease virus (NDV) in a subject, comprising administering to the subject a composition comprising a recombinant NDV expressing a synthetic polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:2, and wherein the genome of the recombinant NDV is at least 95% identical to SEQ ID NO: 3.

7. The method of claim 6 , wherein the synthetic polypeptide has an amino acid sequence at least 98% identical to SEQ ID NO:2.

8. The method of claim 6 , wherein the synthetic polypeptide comprises SEQ ID NO:2.

9. The method of claim 6 , wherein the subject is poultry.

10. The method of claim 9 , wherein the subject is a chicken.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2024
From: YU, QINGZHONG; SPATZ, STEPHEN J.; DUNN, JOHN R.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
Reel/Frame 069667/0858 →
Continuity (2)
Continuation 16848880 · Apr 15, 2020
Related Publication 20220185848A1 · Jun 16, 2022
References Cited (7)
US 20030175291A1 · Kuo · 2003 [cited by examiner]
Huang et al. Recombinant Newcastle Disease Virus as a Vaccine Vector. Poultry Science, 2003, 82:899-906. [cited by examiner]
Huang et al. A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV. Journal of Virology, Sep. 2004, vol. 78, p. 10054-10063. [cited by examiner]
Ross L. Recombinant vaccines against Marek's disease. Avian Pathology (1998) 27, S65-S73. [cited by examiner]
YP_001033956.1 (envelope glycoprotein B [Gallid alphaherpesvirus 2], dated Aug. 13, 2018). [cited by examiner]
Bukreyev et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol. Nov. 2005;79(21):13275-84. [cited by examiner]
GenBank: KM056357.1. Newcastle disease virus isolate ndv61/B1, complete genome. Dated Sep. 28, 2014. [cited by examiner]